This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Yiping Ding: Innovator in Metabolic Disorder Treatments
Introduction
Yiping Ding is a notable inventor based in Changshu, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of treatments for metabolic disorders. His innovative work has led to the creation of a patent that addresses critical health issues.
Latest Patents
Yiping Ding holds a patent for "Cyclic bridgehead ether DGAT1 inhibitors." This invention relates to compounds that are useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1). These disorders include various metabolic conditions. The patent also outlines methods for treating such disorders, along with the compounds and compositions necessary for their treatment.
Career Highlights
Yiping Ding is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in the pharmaceutical industry. His expertise in medicinal chemistry has been instrumental in advancing therapeutic options for patients.
Collaborations
Yiping Ding has collaborated with colleagues such as Sejal Patel and Justin Mao. These partnerships have fostered a collaborative environment that enhances research and development efforts within the company.
Conclusion
Yiping Ding's contributions to the field of medicinal chemistry, particularly through his patent on DGAT1 inhibitors, highlight his role as an innovator in treating metabolic disorders. His work continues to impact the healthcare industry positively.